Replens (glycerin/mineral oil/polycarbophil)
Vaginal Gel With Applicator (Gram)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: glycerin/mineral oil/polycarbophil
Therapeutic class: Vaginal Products
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Replens
Indications
No indications are available for this drug.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Oil-Based Vaginal Prod/Segester-Ethinyl Estradiol (Annovera)
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The use of Annovera (segesterone-ethinyl estradiol vaginal ring) with oil-based vaginal products may alter the vaginal system resulting in increased concentrations of ethinyl estradiol and segesterone because of increased rate of release of segesterone-ethinyl estradiol from the ring. This may lead to contraceptive failure.(1)
CLINICAL EFFECTS: Concurrent use of Annovera (segesterone-ethinyl estradiol) with oil-based vaginal products may lead to decreased effectiveness of contraceptive, producing breakthrough bleeding and unintended pregnancy.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Concurrent use of Annovera (segesterone-ethinyl estradiol) with oil-based vaginal products should be avoided.(1)
DISCUSSION: In a study in 29 females, the concurrent use of Annovera with three different formulations of vaginal miconazole were compared. A single-dose vaginal administration of miconazole vaginal suppository (1200 mg) on Day 8 of Annovera use increased the area-under-the-curve Day8-21 (AUCDay8-21) of ethinyl estradiol by approximately 67%. Administration of a miconazole vaginal suppository (1200 mg) on Day 8 of Annovera use increased the AUCDay8-9, AUCDay8-10, and AUCDay8-21 of ethinyl estradiol by approximately 30%, 32%, and 19%. Administration of a miconazole vaginal suppository (200 mg) on Day 8, Day 9, and Day 10 of Annovera use increased the ethinyl estradiol AUCDay8-11 and AUCDay8-21 by 9% and 21%. Administration of a miconazole vaginal suppository (200 mg) on Day 8, Day 9, and Day 10 of Annovera use increased the segesterone AUCDay8-11 and AUCDay8-21 by 28% and 27%. Water-based miconazole cream had no effect on Annovera. (1)
There are no severe interactions for this drug.
Moderate Interaction: Assess the risk to the patient and take action as needed.
Oil-Based Vaginal Products/Etonogestrel-Ethinyl Estradiol
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The use of Eluryng or Nuvaring (etonogestrel-ethinyl estradiol vaginal ring) with oil-based vaginal products has been associated with ring breakage.(1,2)
CLINICAL EFFECTS: Concurrent use of Eluryng or Nuvaring (etonogestrel-ethinyl estradiol vaginal ring with oil-based vaginal products has been associated with ring breakage. Contraceptive efficacy is not believed to be affected. Vaginal injury including pain, discomfort, and bleeding has been reported in association with ring breakage.(1,2)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: If the contraceptive ring breaks but stays in the vagina, ring effectiveness should not be affected. If a broken ring slips out or is removed, it should not be reinserted. Instead, it should be discarded and replaced with a new ring.(1,2)
DISCUSSION: A single-dose of an oil-based vaginal miconazole nitrate capsule (1200 mg) increased etonogestrel levels by 17% and ethinyl estradiol levels by 16%.(1) These changes in serum levels are not expected to affect efficacy.(3)
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.